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Abstract
Background: The prevalence of microembolic signals (MES) during the acute phase of ischemic stroke and its
influence on outcome is not well studied. The aim of our study was to determine the prevalence of MES, the
different factors that are associated with the presence of MES and the association between MES and outcomes in
stroke patients investigated within 6 hours after the onset of ischemic stroke.
Methods: We included unselected ischemic stroke patients who underwent microemboli-monitoring within six
hours after stroke onset. Microemboli-monitoring of both middle cerebral arteries (MCA) was done for a period of
1 hour using 2-MHz probes applied over the trans-temporal window. Prevalence of MES, predictors for the
presence of MES and the association between MES and various outcome factors were analyzed.
Results: Forty patients were included. The mean age of the patients was 70 years. The prevalence of either
ipsilateral or contralateral MES were 25% (n = 10). The predictors for the presence of MES were older age (OR 9; p
= 0.03), higher NIHSS (OR 28; p = 0.02), intracranial stenosis (OR 10; p = 0.04) and embolic stroke (large-artery
atherosclerosis and cardioembolism on TOAST classification) (OR 7; p = 0.06). MES were not independently
associated with short-term functional outcome, long-term mortality or future vascular events.
Conclusions: MES are moderately frequent following acute ischemic stroke. Microemboli-monitoring helps to
better classify the stroke etiology. However, the presence MES did not have any prognostic significance in this
study.
Background
Previous studies have shown that microemboli to brain
occurs following an ischemic stroke [1-12]. These clini-
cally silent microemboli can be detected as microem-
bolic signals (MES) using transcranial Doppler (TCD).
There is a wide variation in the prevalence of MES after
stroke. A pooled analysis of ischemic stroke patients
with a known source of embolism have shown that the
prevalence of MES in symptomatic ICA stenosis, asymp-
tomatic ICA stenosis and aortic atheroma as 42%, 8%
and 32% respectively [13]. However, the prevalence of
MES also depends on timing of monitoring, showing
higher prevalence when microemboli-monitoring is
done closer to stroke onset [2,3,10]. But studies to assess
t h et r u ep r e v a l e n c eo fM E Si m m e d i a t e l yf o l l o w i n g
ischemic events are lacking. Also, the implications of
MES in the first six hours after stroke onset is not stu-
died before.
T h ec o m m o ns o u r c eo fM E Si st h o u g h tt ob ef r o m
heart (atrial fibrillation, artificial heart valves etc.) or
from an atherosclerotic plaque. While these sources are
major risk factors for symptomatic thrombo-embolic
events, MES per se may not cause symptoms and its
clinical significance is not fully known. There is some
evidence that microemboli may obstruct small arterioles
and lead to subsequent white matter degeneration [14].
Therefore it is important to assess the prevalence and
the significance of MES.
Previous studies have shown that intravenous anti-pla-
telet medications can reduce microemboli [15]. There-
fore it is reasonable to assume that interventions such
as double platelet inhibition, anticoagulation or platelet
inhibition along with anticoagulation may reduce or
abolish microemboli. It will be futile to conduct such
studies without knowing the true prevalence of MES in
various stages of stroke, the type of stroke that are
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boli on stroke outcomes.
T h ea i mo fo u rs t u d yw a st oa s s e s st h ep r e v a l e n c eo f
MES in acute stroke patients within 6 hours after stroke
onset. We also aimed to study the etiology associated
with MES and its significance on functional and survival
outcomes.
Methods
The study was conducted at Haukeland University Hos-
pital, Bergen, Norway for a period of two years between
January 2007 and December 2008. The hospital covers a
well-defined geographic area with a population of
235,000. All patients were admitted to stroke unit under
the department of Neurology.
In this prospective study, we included patients with
ischemic stroke or TIA presented within six hours after
the onset of symptoms. Patients were included whenever
possible, i.e. if an experienced examiner (TTI, LT) was
available, if investigation could be performed in less
than six hrs after symptom onset, and if an adequate
ultrasound window was found.
Microemboli-monitoring using TCD was done earliest
possible according to the availability of the investigators
(TTI & LT). We used Pioneer Nicolet TC 8080 for
TCD examination and microemboli-monitoring. Both
MCA were insonated using a trans-temporal approach.
Signals were obtained from the most proximal part of
MCA (usually at 56 ± 4 mm). The gain was set to the
minimum possible and MES were detected automatically
as “HITS” (high intensity transient signals). Sample
volume length was set at 10 mm. Machine detected
HITS were manually inspected to rule out artifacts. The
monitoring was done continuously for one hour. Pre-
sence of one or more microemboli during the one-hour
monitoring was considered MES positive. Microemboli
was defined using the criteria drawn up by the Interna-
tional Consensus Group on Microembolus Detection
[16].
All patients underwent TCD study of all segments of
MCA and some patients underwent magnetic resonance
angiogram of intracranial vessels. A stenosis above 50%
on either test was considered positive for intracranial
stenosis. TCD criteria used to define 50% stenosis was a
mean velocity over 100 cm/sec.
A neurologist assessed NIHSS at the time of admis-
sion. Eligible candidates received intravenous thrombo-
lysis according to SITS-MOST criteria [17]. Patients
who were not eligible for thrombolysis were treated
with antiplatelet medications after ruling out cerebral
hemorrhage. The choice of antiplatelet medication was
left to the treating neurologist. Risk factors were defined
according to a protocol. Hypertension (HTN) was
defined as treatment with antihypertensive drugs before
stroke onset. Diabetes mellitus (DM) was defined as
treatment with glucose lowering medications or diet
prior to stroke onset, or a fasting serum glucose >7.7
mmol/L during hospital stay.
Active smoking was defined as the use of at least one
cigarette per day prior to stroke onset. History of atrial
fibrillation (AF), previous stroke or TIA, coronary artery
disease and peripheral vascular disease was registered
during hospital stay.
All patients underwent Duplex sonography of the car-
otid arteries. ECG was done on all patients and echocar-
diography was done on patients with suspected cardiac
source of emboli. The etiology of stroke was classified
as large-artery atherosclerosis, cardioembolism, small
vessel occlusion, stroke of other determined etiology
and stroke of unknown etiology based on TOAST cri-
teria. Age was categorized as <65 and ≥ 65 years. Out-
come was measured by modified Rankin Scale (mRS) 7
days after stroke onset or on discharge if discharged ear-
lier. Poor outcome was defined as mRS ≥ 3. Survival
data was obtained from the National Population Registry
of Norway, where all permanent residents are registered.
All causes of mortality were included. Patients were fol-
lowed for a maximum of 2 years for future vascular
event rate and survival analysis.
Informed consent was obtained from all the patients
and the study was approved by the local ethics
committee.
Statistics
Continuous variables are expressed as mean and stan-
dard deviation for parametric variables and as median
and 95%CI for non-parametric variable. Pearson’sC h i -
square test and Fisher exact test were used to assess
odds ratio and significance for fourfold tables. Binary
logistic regression was used to analyze the functional
outcome. Cox-regression analysis was used for the ana-
lysis of survival and future vascular events. Statistical
analysis was performed with SPSS 14.0 software.
Results
A total of 49 patients underwent microemboli-monitor-
ing during the two-year period. Nine (9) patients were
excluded because of poor or absent ultrasound window.
The remaining 40 patients were included in the study.
The mean age (years) of patients with poor or absent
window was higher than the mean age of patients with
an adequate ultrasound window (76.4, 67.9; p = 0.12).
Table 1 shows the general characteristics of the study
population. Ipsilateral or contralateral intracranial steno-
sis was present in 6 patients (15%). The prevalence (95%
CI) of MES on the ipsilateral side was 20 (7-33)%. The
prevalence (95% CI) of MES on the contralateral side
was 10 (11-39)%. The prevalence (95% CI) of MES on
Idicula et al. BMC Neurology 2010, 10:79
http://www.biomedcentral.com/1471-2377/10/79
Page 2 of 5either ipsilateral or contralateral side was 25 (8-29)%.
Twenty four (24) out of total 40 patients underwent
thrombolysis. The prevalence of MES in those patients
who underwent thrombolysis was higher than those
who did not undergo thrombolysis (29.2% versus 18.8%,
p = 0.7).
Table 2 shows the predictors for the prevalence of at
least one MES one either ipsilateral or contralateral side
in various patient subgroups. Patients older than 65
years of age were nine times more likely to have MES
compared to those below 65 years (p = 0.02). Patients
with severe stroke (NIHSS ≥ 14) were 28 times more
likely to have MES compared to those with milder
stroke severity (NIHSS < 14) (p = 0.007). Patients with
intracranial stenosis were 10 times more likely to have
MES compared to those without stenosis (p = 0.007). A
similar analysis of isolated ipsilateral and isolated con-
tralateral MES showed intracranial stenosis as the only
significant predictor of MES (OR = 11, p = 0.006 and
OR = 11, p = 0.001 respectively).
Patients with embolic etiology (cardioembolism or
large-artery atherosclerosis) were seven times more
likely to have MES compared to other etiologies (small
vessel, unknown cause and other causes) based on
TOAST criteria (p = 0.03). Eight out of ten patients
with MES had an embolic source for stroke. The preva-
lence of MES in patients with embolic etiology was
33.3% and that of non-embolic etiology was 12.5%.
None of the patients with lacunar stroke or stroke from
‘other etiology’ (one patient with moyamoya disease and
one patient with carotid dissection) had MES. Out of
nineteen patients with `unknown etiology`, two patients
with insufficient stroke work-up had MES. Figure 1
shows the prevalence of MES in various TOAST sub-
groups. Sex, stroke type (TIA vs. stroke), smoking habit
and pre-existing atrial fibrillation were not associated
with the presence of MES.
On univariate logistic regression analysis, MES were
significantly associated with poor functional outcome
(OR 9, p = 0.017). When the analysis was done after
adjusting for the confounding factors (age, sex and
NIHSS), the association was no more significant (OR
3.4, p = 0.25). Isolated ipsilateral MES and isolated con-
tralateral MES were also not associated with functional
outcomes (OR = 4.3, p = 0.26; OR = 0.95, p = 0.13).
Table 1 General characteristics and the prevalence of
microembolic signals of the study population (n = 40)
Prevalence of ipsilateral microemboli (95% CI) 20 (7-33)
Prevalence of contralateral micromboli (95% CI) 10 (2-20)
Prevalence of ipsilateral or contralateral microemboli (95% CI) 25 (11-39)
Mean age (SD) 70 (15.5)
Sex-male (%) 72.5
Median NIHSS (interquartile percentiles) 7 (3-12)
TIA (%) 5.1
Intracranial stenosis (%) 15
Etiology-TOAST
Large-aretry atherosclerosis (%) 33.3
Cardioembolism (%) 28.2
Small vessel disease (%) 5.1
Other (%) 5.1
Unknown (%) 28.2
Thrombolysis (%) 61.5
Pre-existing conditions
Stroke/TIA (%) 28.9
Atrial fibrillation (%) 16.1
Coronary artery disease (%) 15.4
Hypertension (%) 50
Diabetes mellitus (%) 10.5
Current smokers (%) 24.2
Peripheral vascular disease (%) 9.4
Migraine (%) 23.8
Depression (%) 33.3
NIHSS = National Institute of Health Stroke Scale
TOAST = Trial of Org 10172 in Acute Stroke Treatment
TIA = Transient ischemic attack
Table 2 Prevalence of MES in various patient subgroups
along with OR for the subgroups that are significantly
associated with MES (n = 40).
Group % OR p-value
Age < 65 5.9 9 0.03
≥ 65 36.4
Sex Male 20.7 0.26
Female 36.4
Stroke type Stroke 24.3 0.58
TIA 0
NIHSS 0-7 15 Ref 0.02
8-13 8.3 14
> 13 71.4 28
Intravenous thrombolysis Yes 29.2 0.36
No 18.8
Etiology-TOAST Embolic 33.3 7 0.06
Non-embolic 12.5
Intracranial stenosis No 16.7 10 0.04
Yes 66.7
Previous stroke/TIA No 14.8 4.8 0.06
Yes 45.5
Atrial fibrillation No 23.1 0.13
yes 60
Active Smokers No 28 0.6
yes 25
* OR calculated using Chi-square for dichotomous variables and logistic
regression for polytomous variables.
NIHSS = National Institute of Health Stroke Scale
TOAST = Trial of Org 10172 in Acute Stroke Treatment
TIA = Transient ischemic attack
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On Cox regression analysis, after adjusting for age, sex
and NIHSS, presence of MES were not associated with
mortality (OR 1.9, p = 0.55). Figure 2 shows the survival
curve for patients with and without MES. Two patients
had recurrent ischemic events. None of these patients
had MES at index stroke.
Discussion
Our study shows that the prevalence of MES in stroke
patients with thrombo-embolic etiology is moderately
frequent while the prevalence of MES in non-throm-
boembolic stroke is infrequent in the first six hours
after stroke. One third of the stroke patients with
embolic etiology had MES whi l eo n l yo n ee i g h t ho ft h e
stroke patients with non-embolic etiology had MES.
Eight out of ten patients with MES had either large-
artery or cardio-embolic etiology.
Detection of the source of emboli is important in pre-
venting future strokes. Based on the present stroke clas-
sifications such as the TOAST criteria, more than one
third of the patients falls under the subgroup of ‘unde-
termined etiology’ [18,19]. In two previous studies, the
prevalence of MES in stroke patients with embolic etiol-
ogy (large artery and cardioembolic) was 10% and 43%
while those of non-embolic etiology were 2.9% 19%
[7,8]. The prevalence of MES in lacunar stroke in those
studies were 0% and 17.6%. In our study the prevalence
of MES in embolic, non-embolic (including lacunar) and
lacunar stroke were 33.3%, 12.5% and 0% respectively. A
similar prevalence was also observed in the sub-group of
patients who underwent thrombolysis (37.5% in embolic
etiology and 12.5% in non-embolic etiology). Thus,
detection of MES helps us to better classify the etiology
of stroke. We may assume that MES is moderately sen-
sitive, but highly specific, in detecting embolic stroke
based on the findings from this study as well as the pre-
vious studies [7,8].
The prevalence of microemboli among patients who
underwent thrombolysis was higher than in those who
did not undergo thrombolysis (29.2% versus18.8%), how-
ever did not reach statistical significance (p = 0.36). It is
argued that MES in patients who undergo thrombolysis
may represent fragmentation of thrombus proximal to
insonation by thrombolytic agents. A clear conclusion
cannot be drawn from our study because the association
was not statistically significant.
One of the issues in performing microemboli-monitor-
ing immediately following stroke onset is that it requires
considerable time and manpower to set up the machine
and to perform monitoring constantly. Unless there is a
clear and superior benefit in detecting more patients
with MES or in predicting outcomes, it is futile to per-
form the time-consuming microemboli-monitoring dur-
ing the phase immediately following stroke. A
prevalence of 25% as shown in our study is not consid-
erably higher than in other studies in which monitoring
was done beyond the first six hours after stroke onset.
Our study also failed to shows any association between
MES detected during the acute phase of stroke and
stroke outcomes (functional outcome and survival) or
future vascular events. Thus, the difficulty of performing
microemboli-monitoring along with its uncertain asso-
ciation with stroke outcomes and future vascular events
questions its clinical utility during the acute phase of
stroke. However, this interpretation needs to be taken
cautiously since ours is a single-center study of non-
consecutive stroke patients. This study may be under-
powered to assess the outcomes. Therefore the results
need to be confirmed with larger studies. Also, the
Figure 1 Presence of microemboli and stroke etiology
according to TOAST classification. 1 = Large-artery
atherosclerosis. 2 = Cardioembolism. 3 = Lacunar. 4 = Other. 5 =
Unknown
Figure 2 Survival pattern of patients with and without MES at
admission (n = 40). *Cox-regression survival curve after adjusting
for age, sex and NIHSS.
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tain specific sub-groups such as symptomatic carotid
stenosis, especially those with unstable carotid plaque
[20].
This study has some limitations. We did not include
all consecutive patients admitted within the first six
hours after the stroke. Therefore, the prevalence rate in
our study may not represent the actual prevalence.
Microemboli-monitoring wasd o n eo n l yo n c e .M u l t i p l e
monitoring during successive days following stroke
might yield more patients with microemboli. A single
monitoring also makes it difficult to assess the source of
microemboli in those patients with intracranial stenosis
because microemboli could have originated from a
resolving thrombus. Another limitation is a relatively
small patient population. A large study, however, may
be practically difficult to conduct during the immediate
phase following stroke onset.
Conclusions
Microemboli-monitoring following acute ischemic stroke
helps to better classify the etiology of stroke as embolic
versus non-embolic. The usefulness of microemboli-
monitoring immediately following stroke onset for prog-
nostication seems questionable.
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